FDA Inspection 1012266 — Cangene BioPharma, LLC
The FDA completed an inspection of Cangene BioPharma, LLC on Mar 22, 2017 in Rockville, MD. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Biologics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 22, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Rockville, MD (United States)